Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review highlights that Cyproterone acetate combined with ethinylestradiol is highly effective for treating severe acne and hirsutism in women with hyperandrogenism, and it also provides benefits for cycle control and mood improvement, according to the analysis of 78 studies.

In this study, cyproterone acetate was found to be effective in treating 'idiopathic' hirsutism, while a combination of ethinyloestradiol and lynoestrenol reduced hair growth in fewer patients despite uniformly lowering testosterone levels.

In this study, patients with varying severities of acne, seborrhoea, and hirsutism responded differently to Cyproteronacetate and Ethinyloestradiol treatment, with improvement rates dependent on symptom severity and treatment duration.

This study found that treatment with cyproterone acetate and ethinyl oestradiol increased hair density in women with diffuse androgen-dependent alopecia, particularly when serum ferritin levels were above 40 μg/l.

In this study, treatment with the oral contraceptive containing 30 μg ethinyl oestradiol and 150 μg desogestrel significantly reduced androgen-dependent hair growth in hirsute women over one year.

This study found that an 8-month treatment with a low-dose oral contraceptive significantly reduced testosterone levels and hair growth in women with polycystic ovary syndrome and hirsutism, with minimal side effects.

This review covers the use of combined oral contraceptives, particularly drospirenone, for managing polycystic ovary syndrome and discusses related metabolic controversies without reporting new clinical results.

This study found that the combination of cyproterone acetate and ethinyl estradiol improved hirsutism and acne in women, with SH 8.1041 showing significant results and both treatments being generally well-tolerated.

In this study, women treated for androgen-dependent alopecia with CPA EE2 therapy experienced significant decreases in serum vitamin B12, hemoglobin, and hematocrit levels after six months.

This study found that both cyproterone acetate alone and combined with ethinyl oestradiol reduced androgen levels and slightly increased SHBG binding in women with hirsutism, but showed no difference in hair regrowth rate between the treatments.

This review describes the dermatological uses of the contraceptive ethinylestradiol/chlormadinone acetate for conditions linked to high androgen levels and reports no new clinical results.

This study found that physician knowledge of thromboembolism risk associated with cyproterone acetate/ethinylestradiol was generally high, although it varied for complex or less common topics.

This study found that the combination of ethinylestradiol and desogestrel significantly decreased hair growth and hormone levels in hirsute women, suggesting a relationship between hormone changes and treatment effectiveness.

In this study, 12 months of cyproterone acetate and ethinyl oestradiol treatment significantly reduced hair growth rate and certain hormone levels in hirsute women, though hair density and prolactin levels remained unchanged.

This study found that a combination of cyproterone acetate and ethinyl estradiol over one year did not affect glucose tolerance but increased total cholesterol, HDL cholesterol, and triglycerides in patients with moderate hyperandrogenism.

This study found that most UK women prescribed cyproterone acetate/ethinylestradiol before and after 2013 had conditions aligning with approved indications and prior acne treatment.

This study found that 12 cycles of chlormadinone acetate in hormonal contraceptives significantly improved oily skin and hair quality, enhancing psychosocial well-being in healthy women.

This study found that EE/CPA and EE/DES were both effective in reducing hirsutism in patients with PCOS, with no additional benefit from adding low-dose metformin.

This study found that a combined oral contraceptive containing ethinyl estradiol and desogestrel appeared effective in temporarily treating ovarian hyperandrogenism in adolescents, with reductions in hormone levels and ovarian volume observed.

This case series suggests that EE/CMA 0.03mg/2mg may help manage dermatological disorders related to androgen excess, as evidenced by symptomatic improvements in the four patients treated.

The researchers concluded that after the 2013 EMA recommendation, there was an overall reduction in CPA/EE prescriptions, but no substantial change in patient diagnoses or potential concurrent hormonal contraceptive use.

This publication discusses the political rationale behind the French regulator ANSM's decision to withdraw Diane®-35 from the market, in response to health concerns associated with third-generation oral contraceptives.

Ethinylestradiol/Chlormadinone Acetate is a safe and effective birth control pill that also helps regulate menstrual cycles, reduces period pain, and treats certain skin and hair conditions.

This study reported that the combination of EE-CPA and raloxifene effectively manages PCOS-related infertility, enhancing pregnancy outcomes through improvements in metabolism, sex hormones, ovarian function, and endometrial receptivity, without significantly increasing adverse effects.

This study found that combining 17α-estradiol 0.01% with minoxidil 2% offered no statistically significant advantage over minoxidil alone for treating female pattern hair loss and may increase the risk of menstrual irregularities.

This randomized clinical trial found that both topical ethinylestradiol 0.01% combined with minoxidil 2% and minoxidil 2% alone were similarly effective in enhancing hair growth for female pattern hair loss, though minoxidil alone was better tolerated with fewer side effects over 24 weeks.

This study found that combined hormonal contraceptives containing ethenyl estradiol and cyproterone acetate improved acne, hirsutism, menstrual irregularity, and dysmenorrhea in patients with polycystic ovarian syndrome, with most participants showing significant symptom improvement after 6 to 12 months.

This study found that treatment with oral contraceptives containing 35mg ethinylestradiol and 2mg cyproterone acetate significantly reduced serum AMH levels in women with clomiphene citrate-resistant polycystic ovary syndrome, unlike metformin.

In this study, metformin, pioglitazone, and ethinylestradiol cyproterone all improved various clinical features and quality of life in Pakistani women with PCOS, though no drug significantly reduced hirsutism.

Two women had skin reactions from a hair loss treatment and got better after stopping use.